Cyclobenzaprine optimised release - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine optimised release - Tonix Pharmaceuticals

Alternative Names: TNX-105

Latest Information Update: 17 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Krele Pharmaceuticals Inc
  • Developer Tonix Pharmaceuticals Holding Corp
  • Class Anxiolytics; Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Post-traumatic stress disorders

Highest Development Phases

  • Discontinued Post-traumatic stress disorders

Most Recent Events

  • 15 Nov 2010 TNX 105 will be available for licensing.
  • 15 Nov 2010 Investigation in Post-traumatic stress disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top